4D Molecular Therapeutics FDMT Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's return on invested capital?
- 4D Molecular Therapeutics (FDMT) reported return on invested capital of -51.1% in Q1 2026.
- How has 4D Molecular Therapeutics's return on invested capital changed year-over-year?
- 4D Molecular Therapeutics's return on invested capital increased by 12.1% year-over-year, from -58.2% to -51.1%.
- What is the long-term trend for 4D Molecular Therapeutics's return on invested capital?
- Over 3 years (2022 to 2025), 4D Molecular Therapeutics's return on invested capital has grown at a -11.1% compound annual growth rate (CAGR), from -58.3% to -40.9%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.